Gilead Sciences’ chronic hepatitis B treatment Vemlidy with health insurance benefits

Published: 2017-11-03 15:36:59

Updated: 2017-11-03 15:36:59

Vemlidy(generic name: Tenofovir Alafenamide Fumarate), a Gilead Sciences Korea’s(CEO Seung-Woo Lee) chronic hepatitis B treatment, will receive the national health insurance benefits from the 1^st of November.

Vemlidy, a tenofovir prodrug, was approved from the Ministry of Food and Drug Safety on 16 May with an indication to taking it once daily for the treatment of chronic hepatitis B adult pa...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.